AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9553290 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall closure rate
Number of subjects: 67
Study 8067791 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (2 mg/kg daily for 14 days, then 1 mg/kg on alternate days for 10 weeks)
Number of subjects: 24
Study 8067791 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 24
Study 3054474 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine 10 mg
Number of subjects: 12
Study 3054474 — intervention group
Group type: EXPERIMENTAL
Intervention: Amineptine 200 mg
Number of subjects: 12
Study 3054474 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 150 mcg
Number of subjects: 12
Study 3054474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30738795 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular endothelial growth factor-targeted therapy
Number of subjects: 138
Study 30738795 — intervention group
Group type: COMPARATOR
Intervention: Disease progression defined by RECIST 1.1 criteria
Number of subjects: 138
Study 31422207 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery alone
Number of subjects: 85
Study 31422207 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus adjuvant concurrent chemoradiotherapy (CCRT)
Number of subjects: 85
Study 28813259 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care
Number of subjects: 0
Study 28813259 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher quality of care and more stable placements
Number of subjects: 0
Study 26376285 — intervention group
Group type: EXPERIMENTAL
Intervention: Support condition (reminders of supportive others)
Number of subjects: 0
Study 26376285 — intervention group
Group type: COMPARATOR
Intervention: Control condition (reminders of mere acquaintances)
Number of subjects: 0
Study 23644091 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (n=52) with additional unexcitability (UE) to bipolar pacing at 10 mA and 2-ms pulse width
Number of subjects: 102
Study 23644091 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (n=50) with bidirectional block across the ablation line
Number of subjects: 102
Study 21813917 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-chews (4 chews providing 1,000 mg quercetin, 120 mg epigallocatechin 3-gallate, 400 mg isoquercetin, 400 mg each eicosapentaenoic acid and docosahexaenoic acid, 1,000 mg vitamin C, and 40 mg niacinamide)
Number of subjects: 20
Study 21813917 — intervention group
Group type: COMPARATOR
Intervention: Placebo chews (PL)
Number of subjects: 20
Study 21813917 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-chews
Number of subjects: 20
Study 21813917 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 20
Study 19114542 — intervention group
Group type: EXPERIMENTAL
Intervention: levothyroxine (l-T(4)) replacement therapy
Number of subjects: 95
Study 17031008 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (median dose: 200 IU/d)
Number of subjects: 1179
Study 17031008 — intervention group
Group type: COMPARATOR
Intervention: No vitamin D supplementation
Number of subjects: 1179
Study 15496646 — intervention group
Group type: EXPERIMENTAL
Intervention: Articaine HCl
Number of subjects: 0
Study 10928305 — intervention group
Group type: EXPERIMENTAL
Intervention: ipsapirone (20 mg orally)
Number of subjects: 12
Study 10928305 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 9298055 — intervention group
Group type: EXPERIMENTAL
Intervention: Undiluted vitreous
Number of subjects: 420
Study 9298055 — intervention group
Group type: COMPARATOR
Intervention: Aqueous
Number of subjects: 420
Study 9298055 — intervention group
Group type: COMPARATOR
Intervention: Vitrectomy cassette fluid
Number of subjects: 420
Study 9298055 — intervention group
Group type: EXPERIMENTAL
Intervention: Gram stain from aqueous or undiluted vitreous
Number of subjects: 420
Study 9298055 — intervention group
Group type: COMPARATOR
Intervention: Vitrectomy
Number of subjects: 420
Study 8342392 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (GH), 0.25 IU/kg/week for 6 months (0.125 IU/kg/week during the first month)
Number of subjects: 33
Study 8342392 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (GH)
Number of subjects: 33
Study 8342392 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 33
Study 31192833 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure + counseling
Number of subjects: 55
Study 31192833 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo acupressure + counseling
Number of subjects: 55
Study 31192833 — intervention group
Group type: COMPARATOR
Intervention: Self-help smoking cessation
Number of subjects: 55
Study 28356053 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 62
Study 28356053 — intervention group
Group type: COMPARATOR
Intervention: Sodium valproate
Number of subjects: 62
Study 26610874 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 14236
Study 26610874 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 14236
Study 23848038 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 30
Study 22016919 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-step self-etch systems (ABSE 1-step)
Number of subjects: 0
Study 22016919 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-step self-etch systems (ABSE 2-step)
Number of subjects: 0
Study 22016919 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil S3 Bond (CS3)
Number of subjects: 0
Study 22016919 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (CSE)
Number of subjects: 0
Study 22016919 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Prompt L-Pop (AD)
Number of subjects: 0
Study 19690310 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg oral estradiol (daily)
Number of subjects: 66
Study 19690310 — intervention group
Group type: COMPARATOR
Intervention: 30 mg oral estradiol (daily)
Number of subjects: 66
Study 19690310 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol-stimulated increase in fluorodeoxyglucose F 18 uptake
Number of subjects: 66
Study 16476104 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg once daily)
Number of subjects: 29
Study 16476104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 16476104 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 29
Study 16296255 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45% stannous fluoride gel
Number of subjects: 30
Study 16296255 — intervention group
Group type: COMPARATOR
Intervention: Colgate Total dentifrice slurry (0.30% triclosan, 0.24% sodium fluoride, 2% copolymer)
Number of subjects: 30
Study 16296255 — intervention group
Group type: COMPARATOR
Intervention: Dentifrice slurry without active ingredients
Number of subjects: 30
Study 11505119 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 48
Study 11505119 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 48
Study 11505119 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Enoximone and Dobutamine)
Number of subjects: 48
Study 9134472 — intervention group
Group type: EXPERIMENTAL
Intervention: Norton score
Number of subjects: 185
Study 9134472 — intervention group
Group type: COMPARATOR
Intervention: Waterlow scale
Number of subjects: 185
Study 20830883 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect composite resin restorations with cuspal coverage (buccal and palatal cusps reduced by 2 mm)
Number of subjects: 4
Study 20830883 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect composite resin restorations with only palatal cuspal coverage
Number of subjects: 4
Study 20830883 — intervention group
Group type: COMPARATOR
Intervention: Indirect composite resin restorations (no cuspal coverage)
Number of subjects: 4
Study 3538995 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline + hydroxyzine (240 mg + 7.5 mg)
Number of subjects: 15
Study 3538995 — intervention group
Group type: COMPARATOR
Intervention: Theophylline monohydrate (281.7 mg)
Number of subjects: 15
Study 30384932 — intervention group
Group type: EXPERIMENTAL
Intervention: Flash-free adhesive (APC Flash‐Free Adhesive Appliance System; 3M Unitek)
Number of subjects: 45
Study 30384932 — intervention group
Group type: COMPARATOR
Intervention: Conventional adhesive (APCII Adhesive Appliance System; 3M Unitek)
Number of subjects: 45
Study 27113945 — intervention group
Group type: EXPERIMENTAL
Intervention: Periarticular liposomal bupivacaine injection
Number of subjects: 207
Study 27113945 — intervention group
Group type: EXPERIMENTAL
Intervention: Periarticular injection of bupivacaine/morphine
Number of subjects: 207
Study 27113945 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular injection of bupivacaine/morphine
Number of subjects: 207
Study 25733367 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory phoneme-based computer training program
Number of subjects: 15
Study 25733367 — intervention group
Group type: COMPARATOR
Intervention: Control group (no auditory training)
Number of subjects: 15
Study 22416789 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle counselling from the nurse practitioner and the general practitioner
Number of subjects: 925
Study 22416789 — intervention group
Group type: COMPARATOR
Intervention: Usual care (oral and written information)
Number of subjects: 925
Study 22416789 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle counselling
Number of subjects: 925
Study 20384435 — intervention group
Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP)
Number of subjects: 464
Study 20384435 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of education
Number of subjects: 464
Study 20384435 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of hypertension
Number of subjects: 464
Study 18534051 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP0004 (orally-inhaled DHE)
Number of subjects: 19
Study 18534051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 16798215 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral stapled LVRS with buttressing technique
Number of subjects: 552
Study 16798215 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with air leak
Number of subjects: 552
Study 16798215 — intervention group
Group type: COMPARATOR
Intervention: Patients without air leak
Number of subjects: 552
Study 12803268 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fentanyl (0.1 mg)
Number of subjects: 51
Study 12803268 — intervention group
Group type: COMPARATOR
Intervention: Oral midazolam (5 mg)
Number of subjects: 51
Study 10816215 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated electrogustometry testing on the right side of the tongue
Number of subjects: 97
Study 10816215 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated electrogustometry testing on the left side of the tongue
Number of subjects: 97
Study 8889350 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor (enalapril)
Number of subjects: 0
Study 8889350 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blocker (amlodipine)
Number of subjects: 0
Study 8889350 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blocker (atenolol)
Number of subjects: 0
Study 8889350 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean arterial blood pressure (goal MAP) of either 102-107 mm Hg
Number of subjects: 0
Study 8889350 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean arterial blood pressure (goal MAP) of < or = 92 mm Hg
Number of subjects: 0
Study 8889350 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal biopsy (for participants without contraindication)
Number of subjects: 0
Study 1893319 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard DPT vaccine (25 Lf units of diphtheria toxoid)
Number of subjects: 250
Study 1893319 — intervention group
Group type: COMPARATOR
Intervention: Modified DPT vaccine (10 Lf units of diphtheria toxoid)
Number of subjects: 250
Study 1893319 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 250
Study 1893319 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard DPT vaccine
Number of subjects: 250
Study 1893319 — intervention group
Group type: COMPARATOR
Intervention: Modified DPT vaccine
Number of subjects: 250
Study 6678824 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilazep, 300 mg daily
Number of subjects: 72
Study 6678824 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid, 100 mg daily or dipyridamole, 300 mg daily
Number of subjects: 72
Study 30975379 — intervention group
Group type: EXPERIMENTAL
Intervention: high DHA multi-nutrient supplement and exercise
Number of subjects: 0
Study 30975379 — intervention group
Group type: COMPARATOR
Intervention: placebo supplement and exercise
Number of subjects: 0
Study 30975379 — intervention group
Group type: EXPERIMENTAL
Intervention: high DHA multi-nutrient supplement
Number of subjects: 0
Study 30975379 — intervention group
Group type: COMPARATOR
Intervention: placebo supplement
Number of subjects: 0
Study 28857263 — intervention group
Group type: EXPERIMENTAL
Intervention: BASE programme (Behaviour Analytics & Support Enhancement)
Number of subjects: 283
Study 28857263 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 283
Study 27935924 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific training on cessation techniques
Number of subjects: 1834
Study 27935924 — intervention group
Group type: EXPERIMENTAL
Intervention: Role models for patients
Number of subjects: 1834
Study 27935924 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine advice to quit smoking
Number of subjects: 1834
Study 27935924 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact of tobacco use on advice
Number of subjects: 1834
Study 27935924 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal training on smoking cessation approaches
Number of subjects: 1834
Study 27935924 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of nicotine replacement therapies
Number of subjects: 1834
Study 27935924 — intervention group
Group type: EXPERIMENTAL
Intervention: Attempts to quit smoking
Number of subjects: 1834
Study 24127996 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough and phlegm together
Number of subjects: 5887
Study 24127996 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough with phlegm
Number of subjects: 5887
Study 24127996 — intervention group
Group type: COMPARATOR
Intervention: Cough alone
Number of subjects: 5887
Study 24127996 — intervention group
Group type: COMPARATOR
Intervention: Phlegm alone
Number of subjects: 5887
Study 23052105 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-Solving Treatment (PST) delivered by mental health nurses
Number of subjects: 0
Study 23052105 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC) by general practitioners
Number of subjects: 0
Study 23052105 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-Solving Treatment (PST)
Number of subjects: 0
Study 23052105 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 0
Study 23052105 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis of PST
Number of subjects: 0
Study 20943705 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg aspirin daily, starting on the first day of gonadotrophin stimulation until delivery
Number of subjects: 487
Study 20943705 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily, starting on the first day of gonadotrophin stimulation until delivery
Number of subjects: 487
Study 20943705 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg aspirin
Number of subjects: 487
Study 20943705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 487
Study 17382760 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced education (daily educational e-mails for 27 weeks)
Number of subjects: 537
Study 17382760 — intervention group
Group type: COMPARATOR
Intervention: Bolus education (e-mailed a set of 96 study questions)
Number of subjects: 537
Study 16181824 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone, dobutamine, nitroglycerin, nitroprusside, nesiritide (established drugs approved by the FDA)
Number of subjects: 0
Study 16181824 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (REVIVE, CASINO, SURVIVE trials)
Number of subjects: 0
Study 16181824 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezosentan (RITZ, VERITAS studies)
Number of subjects: 0
Study 16181824 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan (ACTIV-CHF study)
Number of subjects: 0
Study 12434608 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 40
Study 12434608 — intervention group
Group type: COMPARATOR
Intervention: Spinal Anesthesia (SA)
Number of subjects: 40
Study 10353374 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral redundant targets
Number of subjects: 2
Study 10353374 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral and within-field RTE
Number of subjects: 2
Study 8756833 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (300 micrograms)
Number of subjects: 8
Study 8756833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2008954 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol (7.1, 22.5, or 71.4 micrograms/kg)
Number of subjects: 126
Study 2008954 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (4.3, 13.6, or 42.9 micrograms/kg)
Number of subjects: 126
Study 2008954 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol and Midazolam combination (3.6 + 2.2, 11.3 + 6.8, or 35.7 + 21.5 micrograms/kg)
Number of subjects: 126
Study 2008954 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol, Midazolam, and their combination
Number of subjects: 126
Study 6193772 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser photocoagulation
Number of subjects: 67
Study 6193772 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 67
Study 31634868 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (12 sessions, 30 min each for 4 weeks)
Number of subjects: 60
Study 31634868 — intervention group
Group type: COMPARATOR
Intervention: Celebrex (100 mg, 2 times daily)
Number of subjects: 60
Study 31634868 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 60
Study 31634868 — intervention group
Group type: COMPARATOR
Intervention: Celebrex
Number of subjects: 60
Study 31618520 — intervention group
Group type: EXPERIMENTAL
Intervention: Video education
Number of subjects: 205
Study 31618520 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 205
Study 28248850 — intervention group
Group type: COMPARATOR
Intervention: Iron-supplemented group (n=33)
Number of subjects: 96
Study 28248850 — intervention group
Group type: COMPARATOR
Intervention: Iron-supplemented combined erythropoietin group (n=32)
Number of subjects: 96
Study 28248850 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=31)
Number of subjects: 96
Study 25647754 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 30
Study 25647754 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 30
Study 25035343 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 5811
Study 25035343 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 5811
Study 25035343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5811
Study 22658895 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (glargine plus aspart)
Number of subjects: 52
Study 22658895 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control)
Number of subjects: 52
Study 22658895 — intervention group
Group type: EXPERIMENTAL
Intervention: Molar insulin-to-C-peptide ratio (I/C) > 0.175
Number of subjects: 52
Study 22658895 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin and/or thiazolidinedione usage
Number of subjects: 52
Study 22658895 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≥ 60 years
Number of subjects: 52
Study 22658895 — intervention group
Group type: EXPERIMENTAL
Intervention: I/C ≥ 0.175
Number of subjects: 52
Study 22658895 — intervention group
Group type: EXPERIMENTAL
Intervention: Average glucose level ≥ 180 mg/dL
Number of subjects: 52
Study 19407666 — intervention group
Group type: EXPERIMENTAL
Intervention: L-methionine (1 g PO BID in phase 1 and 2 g PO BID in phase 2)
Number of subjects: 51
Study 19407666 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo/placebo and placebo/L-methionine)
Number of subjects: 51
Study 18085911 — intervention group
Group type: EXPERIMENTAL
Intervention: Day hospital (n=154)
Number of subjects: 694
Study 18085911 — intervention group
Group type: COMPARATOR
Intervention: Community residential treatment (n=139)
Number of subjects: 694
Study 18085911 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected day hospital (n=321)
Number of subjects: 694
Study 18085911 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed residential treatment (n=82)
Number of subjects: 694
Study 18085911 — intervention group
Group type: EXPERIMENTAL
Intervention: Index treatment days and 12-step attendance
Number of subjects: 694
Study 18085911 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender and ethnicity
Number of subjects: 694
Study 18085911 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-step attendance
Number of subjects: 694
Study 18085911 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment beyond the index stay
Number of subjects: 694
Study 15351750 — intervention group
Group type: EXPERIMENTAL
Intervention: Information prescription (IP) with computer training and training summary handout
Number of subjects: 197
Study 15351750 — intervention group
Group type: EXPERIMENTAL
Intervention: Information prescription (IP) users
Number of subjects: 197
Study 15351750 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 197
Study 11781675 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterol esters (2.4 g)
Number of subjects: 37
Study 11781675 — intervention group
Group type: EXPERIMENTAL
Intervention: Stanols (2.4 g)
Number of subjects: 37
Study 11781675 — intervention group
Group type: COMPARATOR
Intervention: Dairy spread (control)
Number of subjects: 37